RESEARCH ARTICLE

Olfactory response as a marker for Alzheimer’s disease: Evidence from perceptual and frontal lobe oscillation coherence deficit

Mohammad Javad Sedghizadeh1, Hadi Hojjati1, Kiana Ezzatdoost1, Hamid Aghajan1*, Zahra Vahabi2,3, Heliya Tarighatnia*1

1 Department of Electrical Engineering, Sharif University of Technology, Tehran, Iran, 2 Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran, 3 Memory and Behavioral Neurology Division, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

* aghajan@ee.sharif.edu

Abstract

High-frequency oscillations of the frontal cortex are involved in functions of the brain that fuse processed data from different sensory modules or bind them with elements stored in the memory. These oscillations also provide inhibitory connections to neural circuits that perform lower-level processes. Deficit in the performance of these oscillations has been examined as a marker for Alzheimer’s disease (AD). Additionally, the neurodegenerative processes associated with AD, such as the deposition of amyloid-beta plaques, do not occur in a spatially homogeneous fashion and progress more prominently in the medial temporal lobe in the early stages of the disease. This region of the brain contains neural circuitry involved in olfactory perception. Several studies have suggested that olfactory deficit can be used as a marker for early diagnosis of AD. A quantitative assessment of the performance of the olfactory system can hence serve as a potential biomarker for Alzheimer’s disease, offering a relatively convenient and inexpensive diagnosis method. This study examines the decline in the perception of olfactory stimuli and the deficit in the performance of high-frequency frontal oscillations in response to olfactory stimulation as markers for AD. Two measurement modalities are employed for assessing the olfactory performance: 1) An interactive smell identification test is used to sample the response to a sizable variety of odorants, and 2) Electroencephalography data are collected in an olfactory perception task with a pair of selected odorants in order to assess the connectivity of frontal cortex regions. Statistical analysis methods are used to assess the significance of selected features extracted from the recorded modalities as Alzheimer’s biomarkers. Olfactory decline regressed to age in both healthy and mild AD groups are evaluated, and single- and multi-modal classifiers are also developed. The novel aspects of this study include: 1) Combining EEG response to olfactory stimulation with behavioral assessment of olfactory perception as a marker of AD, 2) Identification of odorants most significantly affected in mild AD patients, 3) Identification of odorants which are still adequately perceived by mild AD patients, 4) Analysis of the decline in the spatial coherence of different oscillatory bands in response to olfactory
Introduction

Alzheimer’s disease (AD) is the most prevalent type of dementia affecting approximately one individual in 10 in the population older than 65 [1]. Early diagnosis of AD is necessary to ensure that the required clinical and social care are provided for affected individuals [2]. AD is known to be associated with the aggregated deposition of surplus amyloid-beta (Aβ) protein, a product of synaptic activity [3], as plaques causing neurotoxic events such as inflammation and synaptic loss, and other neural degenerations linked to another protein, phosphorylated tau [4].

Accumulated levels of these proteins in the brain have been measured as biomarkers for AD through PET imaging of the brain or sampling the cerebrospinal fluid (CSF) [5, 6]. Several neuropsychological tests have also been introduced to evaluate the mental state of subjects in a clinical exam. Mini-Mental State Exam (MMSE) and Mini-Cog are two examples of such tests, which are used by clinicians to evaluate the cognitive skills of the patients and decide upon further evaluation tests [7–9]. Although no single protocol has been established for large-scale screening of AD, there are proposed frameworks for diagnosis based on a set of biomarkers such as those just mentioned [10]. An update to the National Institute on Aging—Alzheimer’s Association (NIA-AA) Research Framework provides additional flexibility for introducing new biomarkers to allow the results of new measurement modality evaluations in observational studies to establish their value in the clinical assessment of AD [11].

In addition to the mentioned assessment methods, previous studies have shown that olfactory deficit is an early symptom of Alzheimer’s disease [12, 13]. Further studies have demonstrated that standard methods of assessing the olfactory system such as sniffing kits can be helpful in distinguishing mild AD patients from healthy individuals [14–16].

The neurodegenerative processes associated with the deposition of neurofibrillary tangles and amyloid plaques in the brain do not progress in a homogeneous fashion [17], and are more prominent in the medial temporal lobe in the early stage of the disease [18, 19]. Interestingly, the medial temporal lobe is the region where olfactory perception also occurs. Therefore, perception of smells is affected more severely in mild AD patients compared to its decline caused by normal aging, and several studies have suggested that olfactory deficit can be used as a biomarker for early diagnosis of AD [20, 21].

Unlike PET imaging or CSF sampling, measuring the odor perception abilities of patients is an inexpensive and non-invasive procedure. However, the perception of odors highly correlates with the culture of the individuals, and hence, the familiarity of subjects with the employed odorants needs to be considered in defining a smell scoring procedure. The University of Pennsylvania smell identification test (UPSIT) [22] proposes a standard sniffing kit for assessing the olfactory function and has been used for studying the olfactory deficit in mild AD patients [23]. However, some of the odors used in this test may be unfamiliar for non-American societies. To address this issue, researchers have proposed alternative scents in modified sniffing kits to create tests that are suitable for their populations of interest [24–26].

A practical issue in administering sniffing kit tests is that they require the participant’s cooperation. Patients with dementia-like symptoms may have difficulty following the written test questions or the clinician’s instructions or may respond erroneously due to not recalling...
the name of an odorant they indeed perceived. Also, the way an examiner interacts with the participant may introduce bias towards specific options in the response sheet [36]. To circumvent the interference of non-olfactory related issues in the performance of the tests, methods relying on EEG recording during the presentation of odorants to participants have been proposed. One such technique is the olfactory event-related potential (OERP) test, in which a sequence of odorants is presented to the participant at regular time instances, allowing the EEG response data to be averaged over several trial intervals for reducing noise and enhancing the fidelity of the recorded data. Several studies have focused on the role of OERP test results as an early biomarker for AD. In [27] OERP waveforms were analyzed to extract features for differentiating mild AD patients and an age-matched control group. In a more recent study [28], OERP test was employed to distinguish between AD and mild cognitive impairment (MCI) patients.

Another method for the differential analysis of EEG data of mild AD patients and healthy participants is coherence analysis. Coherence refers to the functional connectivity of different brain regions and is measured by the synchrony of oscillations recorded at different EEG electrodes. Earlier studies have indicated that the coherence of EEG channels can help in the diagnosis of AD [29–31]. These studies showed that the reduction in the functional connectivity of the brain regions is captured as a decrease in the coherence between EEG channels [32]. Some reports have also assessed the relative value of the coherence of EEG channels for different frequency bands in the classification of mild AD patients and healthy participants [33, 34].

In this paper, we examine the characteristics of olfactory response as markers for the diagnosis of AD through the use of both EEG and behavioral olfactory response data. Our EEG analysis comprises an assessment of the statistical significance of the coherence in the EEG data across the spatial domain for different frequency bands. In the behavioral olfactory response data, our approach identifies the best subset of odorants among those in a localized version of the UPSIT kit (Iran-SIT [16]), which significantly contributes to classifying mild AD patients and healthy participants. MMSE scores are also used as reference for evaluating our olfactory-based results. Single-modality regressors are developed employing the significant components identified in each set of olfactory response data (EEG coherence and behavioral UPSIT) separately. The regressors are age-adjusted to account for the decline in the performance caused by normal aging. Furthermore, by employing the statistically significant components from both modalities, we propose a multi-modal classifier of mild AD patients versus healthy participants, which also regresses the olfactory decline due to aging.

Materials and methods

Fig 1 illustrates an overview of the multimodal data analysis methodology used in our study. Details of our experiment’s protocol are available at “protocols.io” under the DOI number: 10.17504/protocols.io.bi2qkgdw.

Participants

This study was approved by the Review Board of Tehran University of Medical Sciences (Approval ID: IR.TUMS.MEDICINE.REC.1398.524) and all participants gave their written consent to participate in the experiment. Private information of participants including name and date of birth were kept confidential and not used in any of the analyses. Participants were selected among the individuals referring to the memory clinic of Ziaeian Hospital in Tehran with memory performance complaints. All the tests were carried out in the Department of Geriatric Medicine of Ziaeian Hospital. Two expert neuropsychologists assessed all the participants and recorded their smoking history, preferred hand, age, level of education, as well as
any past olfactory problem. Demographic and medical history data were also collected for each participant. Statistical analyses suggested that sufficient sample size for comparing AD and healthy groups with a statistical power of 95% and type I error of 5% is about 7 participants for each group. A total of 52 participants were recruited for the study, and after applying exclusion criteria (as described in the next subsection), twenty-four individuals (age = 72.1 ± 9.0, female = 54.25%), including 11 participants with AD (age = 76.6 ± 9.2, female = 64%) and 13 healthy participants (age = 68.2 ± 6.2, female = 46%) were selected for data analysis. The Mini-Mental State Examination (MMSE), the Clock Drawing Test (CDT), and a verbal fluency test were performed. After the neuropsychological assessment, a neurologist examined the participants and conducted the Functional Assessment Scales Test (FAST) [35].

Then, the participants performed the UPSIT examination and after a few minutes of rest, performed the EEG-based olfactory measurement test. Table 1 shows the overall statistics of...
the participants. Details of the clinical assessment procedure and the MMSE, UPSIT, and EEG-based experiments are described in the following subsections.

Clinical diagnostic assessment

An expert neurologist diagnosed probable Alzheimer’s disease according to the latest guideline of the NIA-AA [36]. AD participants must meet the criteria prescribed for diagnosing dementia as described in [36]. Results of the Mini-Mental State Examination (MMSE) and inquiry about the onset and progressions of the symptoms from the patients and their companions were used by the neurologist to diagnose cognitive impairment. In addition to criteria for dementia, AD participants must also meet the criteria for probable AD dementia. Structural MRI images (1.5 Tesla MR Scanner and a 16-channel HR head coil) were analyzed, and the Medial Temporal Atrophy Scale, White Matter Lesions, and Global Atrophy Scale were used for describing the image. Exclusion criteria were a history of stroke, schizophrenia, major depressive disorders and electroconvulsive therapy (ECT) over the past six months, traumatic brain injury, non-AD neurodegenerative diseases (Parkinson’s disease, Progressive Supranuclear Palsy, Multi-System Atrophy, Cortico-Basal Degeneration), and any history of olfactory pathway disorders. MCI patients were also excluded from this study.

Mini-Mental State Examination (MMSE)

MMSE [37] is a clinical test commonly used for measuring cognitive impairment. During the MMSE test, different memory skills are evaluated, and a score out of 30 is produced. Based on this score and the education level of the patients, clinicians assess the participant’s cognitive skills.

MMSE consists of the following cognitive test categories: Orientation to time, Orientation to place, Registration, Attention and calculation, Delayed recall, Naming, Repetition, Reading, Writing, Visio-spatial, and Commands. A score is given in each category, and the sum of a participant’s scores in all categories is used as the MMSE score. It should be mentioned that due to the low literacy levels of many of the participants in this study, lower MMSE scores were registered in both AD and healthy control groups.

University of Pennsylvania Smell Identification Test (UPSIT)

UPSIT and its modified versions have been employed in previous studies for early diagnosis of AD. Due to the culture-specific nature of smell perception, the reliability of these tests has to be evaluated in different populations [2, 38]. Localized versions of the UPSIT test kit have been introduced in countries such as Brazil [24], Turkey [25], Lithuania [26], and Iran [16] (for an exhaustive review refer to [14]).

To this date, no research results based on the UPSIT kit or other olfactory-based tests have been reported for the detection of AD in the Iranian population. The current study is the first
to utilize a localized version of the UPSIT test (called Iran-SIT) to diagnose AD in its early stages in Iran.

The test kit consists of 24 odors which are each exposed by scratching its corresponding strip. The list of the odors is included in S1 Table in S1 Appendix. After presenting each scent to the participant, four options to select from are provided, and the participant is asked to identify the closest match among these options to the odor that they perceived. As some participants in the study were not able to read the list of options printed in the kit, either because of vision problems or due to illiteracy, the list of options for each odor presentation was read loudly and clearly to the participants, once before and once after the presentation of each odor.

**Classification.** To assess the results of the UPSIT test, we employed a support vector machine (SVM) classifier with a linear kernel to separate mild AD patients from healthy participants based on the UPSIT score and the age of the participants. Normal aging is known to be a major cause for olfactory deficit and hence, when dealing with the UPSIT or other olfactory test results, it is essential to take into account the effect of aging.

Due to the small size of our dataset, we used 5-fold cross-validation to evaluate the accuracy of the classifier. In this evaluation scheme, the dataset is divided into five equal folds, and each time, the label of one fold is predicted using the model trained on data of the other folds.

**Statistical analysis of UPSIT.** The UPSIT score denotes the number of correct answers for each participant. However, among the twenty-four odors of the test, some are probably more effective at separating Alzheimer’s patients from healthy participants. To determine these significant odors, each participant’s answers were converted to a vector of binary elements in which zeros represent wrong answers and ones indicate correct answers. These vectors were divided into two groups of mild AD patients and healthy participants and then t-test was applied to samples from these groups. By doing this, twenty-four p-values corresponding to the presented odors were obtained. To control the false discovery rate (FDR), the Benjamini-Hochberg method was used [39]. The remaining small p-values (p-value < 0.05) indicate odors that are significant in separating the two participant groups. The Scipy and Statsmodels packages were used for statistical analysis and p-values < 0.05 were considered as significant. The full flow of the statistical analysis for identifying significant odors is illustrated in S1 Fig in S1 Appendix and the values behind the corrected p-values are shown in S2 Table in S1 Appendix.

After identifying the significant odors, we performed a linear regression analysis to obtain a modified UPSIT score as a weighted sum of the significant odor scores. The coefficient of each score in the linear regressor is set to maximize the separability of the mild AD patients and healthy participants.

We fitted a linear regression model to each of the mild AD patients and healthy participant groups using the modified UPSIT score and age. Each regression line demonstrates how the olfactory perception is affected by age in the AD or healthy groups.

**EEG-based olfactory measurement**

EEG signals were recorded using a 32-channel Mitsar amplifier. Data were recorded from the Fz, Cz, Pz, and Fp1 electrodes. The Fz, Cz, and Pz channels were chosen based on the results of a similar study [28]. The Fp1 electrode data was used to identify eye movements and eye blinks. The choice of using a limited number of channels in this study was to accommodate for the age and mental condition of many of the participants, so the time to install and confirm the functionality of the electrodes would be kept to a minimum. The channel impedance was maintained under 15 kΩ for each electrode. The EEG sampling rate was 2000 Hz, and electrodes were referenced to the A1 earlobe [40]. EEGLAB was used for data preprocessing [41].
Participants performed an olfactory perception task [42]. During this task, the participant is presented with a sequence of stimuli composed of two different odors, one of which occurring more frequently (standard) and the other being presented rarely (deviant) [43]. Lemon was chosen as the frequent stimulus and Rose as the rare one [28]. Our experimental protocol consisted of a two-second stimulus presentation followed by 8 seconds of rest (pure water) interval. The odors were delivered to the participant using a laboratory olfactometer [44]. The probability of rare stimuli was 0.25 [28]. Each trial (epoch) took 10 seconds, and the whole experiment for each participant consisted of 120 trials and took about 20 minutes. The 90 frequent and 30 rare odors were presented in a random but preset order.

The choice of odors in olfactory experiments is an important issue. When the objective is to test the performance of the olfactory system, odors must be selected so as not to arouse the trigeminal system. This is because the olfactory and the trigeminal systems are interconnected and may interact by intensifying and suppressing each other during exposure to certain stimuli [45]. Therefore, in our experiments, we replaced the eucalyptus odor which was used in other studies [28] with lemon, since eucalyptus excites both the olfactory and trigeminal systems. We also increased the duration of odor presentation to two seconds to allow for regular breathing cycles by the participants (to accommodate for their age and mental condition). The extracted event epochs included one second of pre-stimulus and two seconds of post-stimulus data, following the empirical estimate of the olfactory response latency of about 600–700 milliseconds [46, 47].

EEG preprocessing. Steps involved in preprocessing the data and extracting epochs for further processing are shown in Fig 1b. Signals were filtered to 0.5 to 40.5 Hz and downsampled to 200 Hz. Independent Component Analysis (FastICA [48]) was used for eye blink removal using all recorded EEG channels. One component corresponding to eye blinks was removed from the four components, and the rest were projected back to the electrode space. The resulting signals were segmented into epochs as follows. Each epoch contains one second of pre- and two seconds of post-stimulus onset (600 samples with a sampling frequency of 200 Hz). From the entire task which included 120 epochs, the ones corresponding to the frequent (lemon) odor were selected for further processing. For each subject, this set includes about 90 epochs. Finally, heavily artifact-contaminated epochs were excluded using a semi-automated method of rejecting epochs with high peak-to-average ratios and manually inspecting the remaining epochs.

Coherence analysis. Fig 1c illustrates the flow of data processing to measure the deficit in the spatial coherence of EEG response for the gamma oscillation band. Since coherence analysis involves nonlinear operations, we first filtered the EEG data in the target band in order to mitigate the effects of other frequency bands. Therefore, for the gamma oscillation band, the preprocessed EEG data were filtered using a bandpass (30.0–40.5 Hz) filter. The upper frequency limit of 40.5 Hz was imposed by the EEG recording system which was programmed to remove higher frequency components including the 50 Hz powerline interference. The coherence analysis method was then applied to the gamma band data for the epochs corresponding to the frequent (lemon) stimuli.

For each pair of connections between the four channels, the imaginary part of coherence (ImCoh) was obtained for each frequency using the following equation:

\[
\text{ImCoh}(C_{xy}(f)) = \frac{\text{Im}(P_{xy}(f))}{P_{xx}(f)P_{yy}(f)}/(1)
\]

in which \(P_{xy}(f)\) indicates the cross power spectral density between channels \(x\) and \(y\) for frequency \(f\), and \(P_{xx}(f)\) and \(P_{yy}(f)\) indicate the power spectral densities of channels \(x\) and \(y\) for
frequency \( f \), respectively. The value of \( P_{xy}(f) \) is calculated as follows:

\[
P_{xy}(f) = \sum_{m = -\infty}^{\infty} R_{xy}(m)e^{-ij2\pi ft}
\]

in which \( R_{xy}(m) = E\{x_{n+m}y_n\} \), \(-\infty < n < \infty\) is the cross correlation of the \( x \) and \( y \) channels, and \( E\{\} \) denotes the expectation of its argument. Values of \( P_{xx}(f) \) and \( P_{yy}(f) \) are calculated using similar equations. The values of \( P_{xy}(f) \), \( P_{xx}(f) \) and \( P_{yy}(f) \) are calculated based on FFT analysis according to the periodogram method [49]. In practical terms, each pair of corresponding epochs from the \( x \) and \( y \) channels produces a value of cross power spectral density at each frequency bin. To calculate this value for each epoch, the FFT of the cross correlation function is calculated using one-second segments with 50% overlap using a Hamming window. The resulting set of FFTs are averaged according to the periodogram method [49], the value of ImCoh is calculated for each frequency bin. This value is then averaged across all epochs for each participant. Then, to calculate the coherence deficit in the gamma band, the resulting values are averaged in the range of frequencies of the gamma band to obtain a single number. We refer to this number as the ImCoh value for the gamma band, and it serves as a measure of asynchrony between the \( x \) and \( y \) EEG channels in this band. In order to measure similar coherence deficit values for other oscillation bands such as delta (0.5–3.99 Hz), theta (4.0–7.99 Hz), alpha (8.0–12.99 Hz) and beta (13.0–29.99 Hz), the same calculation method is conducted using respective bandpass filters for each target band and averaging the ImCoh values over the frequencies in that band.

**Statistical analysis of coherence deficit.** A total of 30 coherence values (5 oscillatory bands times six pairs of electrodes: Fp1-Fz, Fp1-Cz, Fp1-Pz, Fz-Cz, Fz-Pz, Cz-Pz) were calculated. The Welch t-test [39] was applied, and \( p \)-values for all the ImCoh values were calculated. Due to the redundancy in these values (data from the six connections have some degree of correlation), we used the Benjamini-Hochberg correction method to control the FDR using an effective sample size calculation method described in Chapter 8 of [39]. ImCoh values with \( p \)-value < 0.05 were considered significant.

To assess the performance of the resulting significant ImCoh values in classifying mild AD patients and healthy participants, an SVM classifier was trained using the significant ImCoh values (beta and gamma ImCoh values for the Fz-Cz connection) as its features.

**Multimodal analysis**

An objective of this study is to propose a multi-modal method for distinguishing mild AD patients from healthy participants based on the two olfactory-based data types. This is to suggest the most efficient combination of olfactory-based tests for diagnosing AD. To achieve this goal, an SVM classifier with a linear kernel was used to separate mild AD patients from healthy participants based on the significant components of the modified UPSIT test and the significant ImCoh values between the EEG electrodes, which were calculated for the beta and gamma frequency bands in the Fz-Cz connection. Since cognitive and olfactory performance declines with normal aging, two approaches were employed to address the presence of any confounding effect caused by the age of the participants. In the first approach, we trained our classifiers disregarding age as a feature. In the second approach, we measured the rate of change of each of our target features (UPSIT scores, beta and gamma ImCoh values) with age in the healthy group, and compensated the same feature in the AD group for the normal aging effect. Evaluation of classifiers based on single- or multimodal features was conducted using 5-fold cross-validation.
Results

A p-value less than 0.05 was used as the cut-off value for the significance of all the stated results. The Scipy and Statsmodels packages were used for all statistical analyses described in the following.

MMSE

Details of the MMSE results are shown in Table 2. This table includes the participant’s age, diagnosis state, total MMSE score as well as the MMSE score in each category. The p-value for each test category is also shown.

UPSIT

The UPSIT scores of the participants were used to classify them into the AD and healthy groups. Similar to other cognitive measures, the UPSIT score also displays a rate of decline with normal aging in healthy participants. As illustrated in Fig 2a, the two groups of participants demonstrate different rates of decline with aging. These rates can be inferred from the slopes of the regressor lines fitted to the scores of each group in this figure. While a noticeable
A drop is observed in the performance of the AD group relative to the healthy group, the rate of decline versus age remains similar. In order to assess the capability of the UPSIT score in discriminating between the AD and healthy groups, two approaches were employed for removing the effect of normal aging. First, age was disregarded and the UPSIT scores of each group’s members were used to create histograms that are shown in Fig 2a (top). Applying a single-feature SVM classifier to these histograms yields an accuracy of 87.5% in classifying the two groups. Second, age-adjusted scores were calculated by measuring residual distances of the scores from the regressor line fitted to the healthy group’s data. Fig 2a (bottom) displays age-adjusted UPSIT data for the two groups, from which the two illustrated histograms were produced, each capturing the residuals of a participant group from the healthy group’s age-regressed line (here shown as a horizontal line due to age adjustment). A single-feature SVM classifier was applied to these histograms and again, an accuracy of 87.5% was achieved in classifying the two groups. These results suggest a relationship between the olfactory functionality (represented by the UPSIT score) and the diagnosis of AD even when the effect of age confound is removed from the data.

As mentioned in the previous section, p-value was calculated for each odor to identify the most sensitive odorants. Two significant odors (p-value < 0.05) were identified (Grape and Chocolate). These odors, as well as their p-values, are shown in Table 3.

We then calculated the modified UPSIT score for each participant by summing the responses to the two significant odors. The resulting modified scores versus age are plotted in Fig 2b (top) for the two groups. Following a similar approach for removing the effect of age, the modified scores were employed to create the two histograms shown in Fig 2b (top), and
employing a single-feature SVM classifier resulted in an accuracy of 70.8% in classifying the
two groups based on the modified scores. This result displays a drop in the performance com-
pared to the case when the entire UPSIT scores were used to classify the two groups. In the sec-
ond approach, the effect of age was adjusted for by measuring the residual distances of all
scores in the two groups from the regressor line fitted to the data of the healthy group. A sin-
gle-feature SVM classifier was then applied to the resulting age-adjusted histograms shown in
Fig 2b (bottom), yielding a classification accuracy of 87.5%. This result shows considerable
improvement comparing with the accuracy of the age-disregarded approach, and is at par with
the results obtained when the entire UPSIT scores were used to classify the two groups.

To analyze which odors can discriminate between mild AD patients and healthy partici-
pants and which odors can still be perceived by mild AD patients, two visualizations of the
UPSIT results are presented in Fig 3. The two significant odors (Grape and Chocolate) are
indicated in both plots. In Fig 3a, the percentage of mild AD patients or healthy participants
who answered each UPSIT odor identification question correctly is plotted. It can be seen that
more than half of mild AD patients correctly identified the smells of Minty Toothpaste, Jas-
mie, Pineapple, and Strawberry. Fig 3b shows the UPSIT results when the participants in
each group are divided into five-year age bins.

**EEG coherence**

The imaginary part of the coherence between each pair of EEG electrodes was calculated for
each of the delta, theta, alpha, beta, and gamma frequency bands. This value is an indication of
the lack of temporal synchrony between two signals. Fig 4a and 4b illustrate sample epochs in
which 13–30 Hz and 30–40.5 Hz filters were respectively used to extract beta and gamma band
components from the data of the Fz and Cz electrodes of one AD patient and one healthy part-
icipant. As these plots demonstrate, the beta and gamma components recorded by the two
electrodes closely match each other in phase for the data of the healthy participant while the
data of the AD patient contains intervals of clear out-of-phase behavior for these components.
The overall measure used as the imaginary part of coherence (ImCoh) for a participant in a fre-
quency band is calculated as the mean of the imaginary parts of coherence across the frequency
band and averaged for all the frequent odor epochs used in the analysis.

The ImCoh values were calculated for each of the five frequency bands between each pair of
electrodes in each participant’s EEG data. In order to assess the effect of age on the synchroni-
zection behavior of the brain as measured by pairwise ImCoh values, we employed a regressor
fitting approach similar to the UPSIT analysis. Fig 4c and 4d show the regressor lines fitted to
the beta and gamma ImCoh values for the healthy and AD groups. For each frequency band,
histograms of ImCoh values were plotted for both cases when age is disregarded or when its
effect is removed from the data according to the normal aging change. Each of these methods
aims to remove any confound effect caused by normal aging from the data of AD patients.
These age-removed beta- and gamma-band ImCoh values are used to train multi-modal classi-
fiers (with and without the UPSIT scores), the results of which are described in the next
section.

| Odorant       | p-value  |
|---------------|----------|
| Q6 (Grape)    | <0.05    |
| Q21 (Chocolate)| <0.05    |

https://doi.org/10.1371/journal.pone.0243535.t003
Fig 3. a) Percentage of correct answers for each UPSIT (Iran-SIT) odor identification question. The x-axis denotes the tested odors and is sorted from the left by the number of correct answers that the mild AD patients gave. Hence, the leftmost odor is the one that the mild AD patients identified most. The y-axis is the percentage of correct answers to each odor identification question in each group. Two odors that are statistically significant in distinguishing between mild AD patients and healthy participants are denoted by + and x marks. b) The number of correct answers for each UPSIT (Iran-SIT) odor identification question divided into five-year age bins. The shade of each bin denotes the number of correct answers. Green (light) pixels indicate that most participants in the corresponding age bin answered the question correctly, and the blue (dark) pixels suggest that most of the participants were unable to identify the presented odor. The upper diagram is for the healthy participants, and the lower diagram is for the mild AD patients. The two statistically significant odors are denoted by dashed boxes.

https://doi.org/10.1371/journal.pone.0243535.g003
Fig 4. a) Beta-band component of a sample epoch from the data of the Fz and Cz electrodes for one AD (top) and one healthy (bottom) participant. b) Gamma-band component of a sample epoch from the data of the Fz and Cz electrodes for one AD (top) and one healthy (bottom) participant. c) Top: Regression of beta-band ImCoh value with age. Values for the two groups are shown as histograms. Bottom: Age-adjusted beta-band ImCoh values are shown as histograms for the two groups. d) Top: Regression of gamma-band ImCoh value with age. Values for the two groups are shown as histograms. Bottom: Age-adjusted gamma-band ImCoh values are shown as histograms for the two groups. e) Statistical significance of the gamma-band ImCoh value difference between mild AD patients and healthy participants. The Fz-Cz connection is the most significant connection with p-value < 0.05. f) The ImCoh value of the Fz-Cz connection measured in each frequency band. Statistically significant frequency bands are denoted by + and x marks.

https://doi.org/10.1371/journal.pone.0243535.g004
Statistical analysis indicated the ImCoh value between the Fz and Cz channels to possess the highest significance in separating the two groups of mild AD patients and healthy participants, with the gamma and beta ImCoh values having p-values less than 0.05. Fig 4e illustrates the relative significance of the six electrode-pair connections for the gamma-band ImCoh values, with the best p-value in the Fz-Cz connection. Fig 4f shows the mean and the standard deviation of the ImCoh values for all five frequency bands for the Fz-Cz connection across the AD and healthy groups. The beta and gamma ImCoh values for this connection offer significant discrimination power between the two groups.

Multimodal analysis

We employed three multimodal classification methods based on the significant ImCoh values measured between the Fz and Cz channels in the beta and gamma frequency bands, and the total or modified UPSIT scores. Using single-feature classifiers based on the total or modified UPSIT scores resulted in classification accuracies reported in the UPSIT section earlier, which are included in Table 4 for comparison with multi-modal results. Table 4a includes classification results for the cases in which age was disregarded as a feature. In Table 4b, classification results are shown for the cases in which all measured features are age-adjusted according to the methods described earlier.

The multimodal classifier which employs the beta- and gamma-band ImCoh values across the Fz-Cz electrode pair and the modified UPSIT score outperforms other classifiers in terms of accuracy. This means that the data collection protocol corresponding to this classifier only requires that the participants answer two questions in the UPSIT test and that the EEG data be recorded from 3 electrodes (Fz, Cz, Fp1) and a reference (A1), offering a convenient procedure for examining elderly participants. The performance of the proposed multimodal classifier is comparable to the MMSE-based assessment used routinely in clinical examinations.

In addition, the modified UPSIT classifier performs equally well compared to the total UPSIT score with age adjustment. This shows that even by using a limited number of selective odors, clinicians can obtain valuable indications about the state of a patient. However, a more extensive study is needed to further assess the validity of this claim.

In order to analyze how correlated the UPSIT score and the Fz-Cz beta and gamma ImCoh values are with the clinical MMSE score, these values for all participants are plotted versus

| Table 4. Classification accuracy for different modalities and the multi-modal analysis based on significant components of each modality. a) Feature data were used for classification disregarding the age of the participants. b) Residuals of each feature relative to its corresponding healthy group regressor were used for classification. | Accuracy (%) | AUC |
|---|---|---|
| a) Classification Results (age-disregarded) | | |
| Total UPSIT | 87.5% | 0.91 |
| Modified UPSIT | 70.8% | 0.84 |
| Beta and Gamma ImCoh in Fz-Cz | 75.0% | 0.85 |
| Beta and Gamma ImCoh in Fz-Cz + Total UPSIT | 87.5% | 0.9 |
| Beta and Gamma ImCoh in Fz-Cz + Modified UPSIT | 91.7% | 0.96 |
| b) Classification Results (age-adjusted) | | |
| Total UPSIT | 87.5% | 0.90 |
| Modified UPSIT | 87.5% | 0.85 |
| Beta and Gamma ImCoh in Fz-Cz | 79.2% | 0.85 |
| Beta and Gamma ImCoh in Fz-Cz + Total UPSIT | 83.3% | 0.87 |
| Beta and Gamma ImCoh in Fz-Cz + Modified UPSIT | 91.7% | 0.97 |

https://doi.org/10.1371/journal.pone.0243535.t004
MMSE scores in Fig 5. The Pearson’s correlation coefficient between the UPSIT and MMSE scores is 0.71 with a p-value of 0.0001, between the beta-band ImCoh value and the MMSE score is -0.58, and between the gamma-band ImCoh value and the MMSE score is -0.55.

**Discussion**

Diagnostic methods such as PET, FDG-PET [50, 51] and MRI imaging and CSF sampling are expensive [52]. In particular, CSF sampling involves an invasive procedure, making it impractical for longitudinal studies requiring repeated sampling. The proposed olfactory-based methodology in this paper is convenient to conduct and has considerably lower cost. It is also more accommodating for elderly patients as both the behavioral and EEG tests only require a small number of measurements. It hence provides a viable solution for monitoring the progress of the disease in a patient over time, and offers opportunities for longitudinal research studies.

In this study, we showed that the grape and chocolate odors could discriminate between mild AD patients and healthy participants with good accuracy. Earlier studies have assessed the ability of different scents in similar tasks. For example, the study by Kjelvik et al. [2] identified some significant odors, which interestingly, chocolate was among them. A proposition for conducting olfactory-based studies would hence be to perform experiments in culturally-diverse groups of populations and identify the marker odors which are significant universally and those best suited for each culture or geography.

We also identified odors in our study which more than half of our mild AD patients could still perceive and successfully recognize. Understandably, a survey of a larger population is needed to identify such odors with more confidence. An interesting application for this set of scents would be to include them in olfactory assessment tests to discriminate between mild AD patients and individuals with anosmia or non-AD neurodegenerative diseases which can lead to the loss of olfactory functionality.

It should be noted that some odors could not be correctly identified by either of the healthy and AD groups. A reason for this lack of performance by the healthy participants might be the unfamiliarity of the study group with certain scents. For instance, both the AD and healthy groups were unable to identify the Coca-Cola odor because most Iranian elderly may have not...
experienced this smell in their daily life. These non-discriminating odors can be replaced in future sniffing kits by other scents to improve the performance of the test.

A known issue with interactive tests such as UPSIT is that the deficit in the perception of odors can be confounded by memory and cognitive impairment affecting the recall of the odor or its name. Nonetheless, the UPSIT experiment proved to possess sufficient discriminating power for the two subject groups in our study. Moreover, the fact that responses by the AD group differ considerably across the set of odors provides additional clues about the progression of the impairments associated with the olfactory perception through the advancement of the disease. The above points justify the inclusion of the UPSIT test in the studies on AD progression.

On the other hand, the mentioned confound issue is totally mitigated in the EEG experiment part of our study which does not involve verbal interactions with the subjects for identifying the names of the odors. Identifying biomarkers in the EEG signal in response to olfactory stimulation is indeed a major thrust of our study. The combined use of features from the UPSIT and EEG tests improved the classification accuracy by about 4 percent for the total UPSIT score and about 12 percent for the modified UPSIT score over the results of EEG alone. Another gain offered by the UPSIT experiment was to allow the examination of a set of 24 odors while the EEG experiment was conducted using 2 odors. The two significant odors identified in our analysis of the UPSIT data can be used to define a simple interactive olfactory screening test or as the two odors used in EEG recordings in the future.

The result of EEG-based olfactory assessment suggested that the coherence in the gamma and beta bands significantly differs between mild AD patients and healthy participants. This result is in agreement with the evidence about the roles that the gamma and beta bands play in cognitive functions of the brain, and their deficit resulting from the neurodegenerative effects of AD. The high-frequency gamma oscillations (30–100 Hz) and the beta oscillations (13–30 Hz) appear to be particularly well suited for the maintenance of functions in the brain that involve binding the processed data from different sensory modules or elements stored in the memory [53]. Multi-sensory data integration [54, 55], attentional sensory selection [56–58], working memory association [59], and generation of long-term memory through associations embedded as synaptic weight adaptation [60, 61], are all performed under the gamma and beta oscillatory regimes in the neuronal populations involved [53].

Employing high-frequency oscillations in functions that access and combine data from multiple sites in the brain is not a coincidence; the resolution that high-frequency oscillations such as the beta and gamma bands offer in their phase allows for fine-tuned coding of relative arrival times and latencies involved in accessing multiple threads of data and hence allows for effective input selectivity through high-precision control of spike timing [53, 62, 63].

Earlier studies of the neurodegeneration mechanisms affecting the olfactory perception in Alzheimer’s disease have indicated three possible candidates: 1) Disruption in the olfactory bulb functionality [19], 2) Weakening of the feedforward data circuitry in the medial temporal lobe [18, 19], and 3) Deficiency in the inhibitory feedback function of interneurons emanating from the frontal lobe [64, 65]. The EEG analysis results of our study establish an evidence for the significance of the third explanation, indicating loss of synchronous oscillations in the frontal lobe as an early marker of AD.

Desynchronized neural activity and disruption of gamma oscillations have been observed in both human mild AD patients [64, 66–68] and the AD mouse models [69–71]. As neuronal connectivity is affected by the accumulation of amyloid-β in the extracellular space [72], considering such aggregation across a large population of neurons allows to model AD as a network operation deficiency problem [73]. In such models, large inhibitory circuits operating under high-frequency regimes turn into subpopulations that may produce these oscillations.
without synchrony with each other. As illustrated in Fig 6, amyloid-β plaques are accumulated between neuronal populations in the frontal lobe, resulting in desynchronized inhibitory feedback to earlier layers. In [74] the deficit in coherence between oscillations measured by EEG electrodes across the scalp in different frequency bands has been proposed as a diagnostic marker of dementia caused by Alzheimer’s disease.

While it is still a matter of debate whether these deficits in high-frequency oscillations are a consequence of the underlying disease progression or that they indeed play a causal role in inducing more biological changes that promote the disease [72], the deficit in the high-frequency oscillations can be associated on the functional level with the lowered binding activity in the cortex, causing the known symptoms of AD such as cognitive decline and dementia. Our study revealed the significance of the gamma and beta band coherences in separating mild AD patients and healthy participants and showed the difference to be more significant across the spatial range measured by the Fz and Cz electrodes. This is the scalp region close to the cortical areas known to be involved in many cognitive functions.

Our study showed that the olfactory deficit could be a fairly accurate marker for AD when behavioral assessment results are combined with the coherency results of the EEG recording. The accuracy of the proposed multi-modal classifier is significantly above the chance level (91.7%). Even if we develop a classifier based on the MMSE scores—which is based on tests that directly evaluate the participant’s memory and cognition—we may not always reach 100% accuracy. A common issue in performing the MMSE test is that some of its questions require reading and writing skills and therefore, illiterate subjects cannot get any scores from those parts. Also, running the test requires interaction between the participant and the memory specialist, increasing the probability of introducing bias during the test. Unlike MMSE, the proposed method in this study requires much less interaction and the behavioral olfactory assessment (UPSIT) test can be carried out even by the participants themselves if they have the ability to read the questions.

Fig 6. Deposition of amyloid-β plaques in the frontal lobe leads to the weakening of neuronal connections. Neuronal populations are still working, but they are not synchronous enough to send effective inhibitory feedback to earlier processing layers.

https://doi.org/10.1371/journal.pone.0243535.g006
Limitations

We have demonstrated the suitability of our methodology in identifying mild AD patients in a limited study on the Iranian population. The proposed method needs to be applied to a bigger population using a larger set of odorants in order to further validate and map out the usefulness of olfactory-based biomarkers in the diagnosis of AD. Furthermore, a larger-cohort study can reveal the effectiveness of our methodology when patients suffering from non-AD dementia or moderate and severe AD patients are also present in the study.

As odor perception is a culture-dependent phenomenon, the exact results derived in our study may not be directly applicable to different populations. A more comprehensive study comprising of populations of participants from different cultural backgrounds is needed to verify the validity of the proposed approach in general, and the significance of the individual scents or other features used in our regressors and classifiers in particular.

A related notable remark is that while the results of the smell identification test (UPSIT) may have strong cultural dependencies, the EEG-based coherence analysis may prove to be a relatively more robust procedure. This is due to the fact that higher-level functions of the brain are represented in the coherence values measured in the EEG analysis, and some level of abstraction from the particular smells that are perceived may be represented in these measurements.

Another limitation of the smell identification test is that successfully answering questions in it involves both the perception of the presented odor as well as its recognition through a memory recall process. This indicates an inherent ambiguity in this test between a lack of perception of the presented smell and failure to identify the name of the odor which may have indeed been perceived. The EEG-based olfactory assessment is advantageous in this aspect to the UPSIT test as it mainly focuses on the perception ability and not the identification or naming functions.

Extensions

One interesting extension of this work is to repeat the EEG-based experiments using the two odors (chocolate and grape) which were identified in the olfactory recognition task as significant and compare the results of the coherence analysis with the current results. As these two odors best separate the two groups of participants, it is interesting to see any gains their usage may provide to the EEG-based coherence results.

An essential extension to the EEG analysis is to examine other approaches, such as the difference between the responses to the two odorants within each group of mild AD patients and healthy participants. There are two possible ways to derive these differences. One is to repeat the current coherence-based approach separately for each of the odorants. The other is to make the comparison directly in the temporal domain of the recorded EEG data after artifact and noise removal. Possible advantages of these odorant-differential analyses may include the additional dimension that they provide as the difference in responses to the two presented odors. To perform this extension, it is better to conduct the experiments with a sequence of odors in which both odorants are presented randomly with equal probabilities so the number of epochs related to the two odorants would be comparable.

Another possible domain for extending the EEG-based olfactory test is to repeat the experiment for each participant in more than one session and use different pairs of odorants in each experiment. This allows for studying the sensitivity map of each participant relative to different odors. Running an experiment with more than two odorants presented by the same olfactometer is a possibility but requires modifications in the design of the olfactometer.
On the cohort design side, a necessary extension is to recall the participants for another round of experiments after a period of six to twelve months and perform longitudinal analyses to study the correlation between the olfactory decline and the progress of the disease in each patient. Another critical extension that can further evaluate the specificity power of the proposed approach is to include a third participant group consisting of non-AD MCI patients and examine the single- and multi-modal analysis methods of the current study in discriminating the three groups from one another. These two latter extensions are within the scope of our ongoing data collection campaign. Any additional results achieved in each of these extended studies will be provided in future reports.

Conclusions
In this paper, we have demonstrated the efficacy of an inexpensive methodology for evaluating the olfactory deficit in the elderly population for being utilized as a marker of AD with good accuracy. Our proposed approach combines behavioral olfactory data with EEG measurements to yield an accurate assessment of the participant’s state.

Statistical analysis of the results of the smell identification test yields two odors (Chocolate and Grape) as significant (p-values < 0.05) from a set of 24 odorants. The EEG coherence analysis indicates the gamma and beta bands to be significant (p-values < 0.05) in the link between the Cz and Fz channels, with the gamma band possessing a higher significance. The proposed multi-modal classifier yields an accuracy of 91.7% in separating mild AD patients from healthy participants.

The accessibility and low cost of the proposed procedure allow for large-scale screening of AD in different geographical regions, a looming necessity across the world as the aging population is rapidly expanding. Furthermore, the results of this work can provide researchers with new insights about the relationship between AD progression and olfactory deficit and can lead to new treatment methods based on olfactory stimulation.

Supporting information
S1 Appendix.
(ODC)

Acknowledgments
The authors would like to thank Ziaeian Hospital in Tehran for providing staff time and equipment for data collection in this study. We are grateful to the patients and their families who participated in this study.

Author Contributions
**Conceptualization:** Hamid Aghajan.

**Data curation:** Mohammad Javad Sedghizadeh, Hadi Hojjati, Kiana Ezzatdoost, Zahra Vahabi, Heliya Tarighatnia.

**Formal analysis:** Mohammad Javad Sedghizadeh, Hadi Hojjati.

**Investigation:** Zahra Vahabi.

**Methodology:** Mohammad Javad Sedghizadeh, Hadi Hojjati, Kiana Ezzatdoost, Hamid Aghajan, Zahra Vahabi.

**Supervision:** Hamid Aghajan, Zahra Vahabi.
Validation: Mohammad Javad Sedghizadeh, Zahra Vahabi.

Visualization: Mohammad Javad Sedghizadeh, Hadi Hojjati, Kiana Ezzatdoost.

Writing – original draft: Mohammad Javad Sedghizadeh, Hadi Hojjati, Kiana Ezzatdoost, Hamid Aghajan.

Writing – review & editing: Hamid Aghajan.

References

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s and Dementia. 2013; 9: p. 63–75. https://doi.org/10.1016/j.jalz.2012.11.007 PMID: 23305823

2. Kjelvik G, Sando SB, Aasly J, Engedal KA, Whit LR. Use of the Brief Smell Identification Test for olfactory deficit in a Norwegian population with Alzheimer’s disease. Psychiatry, Int. Journal of Geriatric. 2007; 22: p. 1020–1024.

3. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci. 2011; 14(6): p. 750–756. https://doi.org/10.1038/nn.2801 PMID: 21532579

4. Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci. 1996; 777: p. 57–64. https://doi.org/10.1111/j.1749-6632.1996.tb34401.x PMID: 8624127

5. Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimer’s & Dementia. 2018; 14(11): p. 1505–1521. https://doi.org/10.1016/j.jalz.2018.07.220 PMID: 30316776

6. Cole A, Van Hulle CA, Chin NA, Blazel H, Clark LR, Lazar KK, et al. Lumbar Puncture Side Effect Rates in a Research Setting. Alzheimer’s and Dementia. 2018; 14(7): p. 1180–P1181.

7. Chua XY, Choo RWM, Ha NHL, See SL, Yap PKK. Mapping modified Mini-Mental State Examination (MMSE) scores to dementia stages in a multi-ethnic Asian population. International Psychogeriatrics. 2019; 31(1): p. 147–151. https://doi.org/10.1017/S1041610218000704 PMID: 30017004

8. Seitz DP, Chan CCH, Newton HT, Gill SS, Herrmann N, Smallegaard N, et al. Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting. Cochrane Systematic Review. 2018;: p. 1465–1858.

9. Jack CR, Wiste HJ, Thernau T. M., Weigand SD, Knopman DS, Mielke MM, et al. Association of Amyloid Tau, and Neurodegeneration Biomarker Profiles with Rates of Memory Decline Among Individuals Without Dementia. JAMA. 2019; 321(23): p. 2316–2325. https://doi.org/10.1001/jama.2019.7437 PMID: 31211344

10. Counts SE, Ikonomovic MD, Mercado N, Vega IE, Munson EJ. Biomarkers for the Early Detection and Progression of Alzheimer’s Disease. Neurotherapeutics. 2017; 14: p. 1007–1016 PMID: 27738903

11. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. The Journal of the Alzheimer’s Association. 2018; 14(4): p. 535–562.

12. Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer’s disease at follow-up. American Journal of Psychiatry. 2000; 157(9): p. 1399–1405. https://doi.org/10.1176/appi.ajp.157.9.1399 PMID: 10964854

13. Hummel T, Landis BN, Hüttenbrink KB. Smell and taste disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2011; 10. https://doi.org/10.3205/cto000077 PMID: 22558054

14. Silva MM, Mercer PBS, Witt MCZ, Pessoa RR. Olfactory dysfunction in Alzheimer’s disease Systematic review and meta-analysis. Dementia e Neuropsychologia. 2018; 12(2): p. 123–132. https://doi.org/10.1590/1980-57642018dn12-020004 PMID: 29988355

15. Zou YM, Lu D, Liu LP, Zhang HH, Zhou YY. Olfactory dysfunction in Alzheimer’s disease. Neuropsychiatric Disease and Treatment. 2016; 12: p. 869–875. https://doi.org/10.2147/NDT.S104866 PMID: 27143888

16. Taherkhani S, Moztarzadeh F, Mehdizadeh Seraj J, Hashemi Nazari SS, Taherkhani F, Ghareshaghi J, et al. Iran Smell Identification Test (Iran-SIT): a Modified Version of the University of Pennsylvania Smell Identification Test (UPSIT) for Iranian Population. Chemosensory Perception. 2015; 8(4): p. 189–191.
17. Attems J, Jellinger KA. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clinical Neuropathology. 2006; 25: p. 265–271. PMID: 17140156
18. Brun A, Gustafsson L. Distribution of cerebral degeneration in Alzheimer’s disease. A clinicopathological study. Archiv fur Psychiatrie und Nervenkrankheiten. 1976; 223: p. 15–33. https://doi.org/10.1007/BF00367450 PMID: 828039
19. Mattsson N, Palmqvist S, Stomrud E, et al. Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology. 2019; 76(11).
20. Talamo BR, Rudel R, Kosik KS, Lee VM, Neff S, Adelman L. Pathological changes in olfactory neurons in patients with Alzheimer’s disease. Nature. 1989; 337: p. 736–739. https://doi.org/10.1038/337736a0 PMID: 2465496
21. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease. A meta-analysis of olfactory functioning in Alzheimer’s disease and Parkinson’s disease. Arch Neurol. 1998; 55: p. 84–90. https://doi.org/10.1001/archneur.55.1.84 PMID: 9443714
22. Doty RL. The Smell Identification Test Administration Manual. 1995.
23. Velayudhan L, Pritchard M, Powell JF, Proitsi P, Lovestone S. Smell identification function as a severity and progression marker in Alzheimer’s disease. International Psychogeriatrics. 2013; 25(7): p. 1157–1166. https://doi.org/10.1017/S1041610213000446 PMID: 23597130
24. Silveira-Moriyama L, Azvedo AM, Ranvau R, Barbosa ER, Doty RL, Lees AJ. Applying a new version of the brazilian-portuguese UPSIT smell test in Brazil. Arquivos de Neuro-Psiquiatria. 2010; 68: p. 700–705. https://doi.org/10.1590/S0004-282X2010000500005 PMID: 21049178
25. Oniz A, Erdogan I, Ikiz AO, Evirgen N, Ozgoren M. The Modified Sniffin’ Sticks Test in Turkish Population Based on Odor Familiarity Survey. Journal of Neurological Sciences. 2013; 30: p. 270–280.
26. Čičekienė J, Vaičiūnas Ž, Rastenytė D. Development of the Lithuanian Version of Sniffin’ Sticks 12 Odor Identification Test. Medicina (Kaunas). 2018; 54(2): p. 13. https://doi.org/10.3390/medicina54020013 PMID: 30344244
27. Morgan CD, Murphy C. Olfactory event-related potentials in Alzheimer’s disease. Journal of the International Neuropsychological Society. 2002; 8: p. 753–763. https://doi.org/10.1017/S1355617702860039 PMID: 12240739
28. Invitto S, Piraino G, Ciccarese V, Carmillo L, Caggiala M, Trianni G, et al. Potential Role of OERP as Early Marker of Mild Cognitive Impairment. Frontiers in Aging Neuroscience. 2018; 10: p. 272. https://doi.org/10.3389/fnagi.2018.00272 PMID: 30271339
29. Adler G. Bassem S, Jacevic A. EEG coherence in Alzheimer’s dementia. J Neural Transm (Vienna). 2003; 110: p. 1051–58. https://doi.org/10.1007/s00702-003-0024-8 PMID: 12298837
30. Chen CC, Hsu CY, Chiu HW, Hu CJ, Lee TC. Frequency power and coherence of electroencephalography are correlated with the severity of Alzheimer’s disease: A multicenter analysis in Taiwan. J Formos Med Assoc. 2015; 114: p. 729–735. https://doi.org/10.1016/j.jfma.2013.07.008 PMID: 23969043
31. Leuchter AF, Spar JE, Walter DO, Weiner H. Electroencephalographic spectra and coherence in the diagnosis of Alzheimer’s-type and multi-infarct dementia. A pilot study. Arch Gen Psychiatry. 1987; 44: p. 993–998. https://doi.org/10.1001/archpsyc.1987.01800230073012 PMID: 3314776
32. Wang R, Wang J, Yu H, Wei X, Yang C, Deng B. Decreased coherence and functional connectivity of electroencephalograph in Alzheimer’s Disease. Chaos. 2014; 24. https://doi.org/10.1063/1.4896095 PMID: 25273216
33. Musaeus CS, Nielsen MS, Osterbye NN, Hogh P. Decreased Parietal Beta Power as a Sign of Disease Progression in Patients with Mild Cognitive Impairment. J Alzheimers Dis. 2018; 65: p. 457–487. https://doi.org/10.3233/JAD-180300 PMID: 29991135
34. Musaeus CS, Engedal K, Hogh P, Jelic V, Mrup M, Naik M, et al. EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia due to Alzheimer’s Disease. J Alzheimers Dis. 2018. https://doi.org/10.3389/fpsyg.2018.01033 PMID: 30344244
35. Reisberg B. Functional assessment staging (FAST). Psychopharmacology Bulletin. 1988; 24: p. 653–659. PMID: 3249767
36. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7(3): p. 263–269. https://doi.org/10.1016/j.jalz.2011.03.005 PMID: 21514250
37. Folstein M, Folstein, McHugh P. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. November 1975.; p. 189–198. https://doi.org/10.1016/0022-3965(75)90026-6 PMID: 1202204
38. Makowska I, Kloszewska I, Grabowska A, Szatkowska I, Rymarczyk K. Olfactory deficits in normal aging and Alzheimer’s disease in the polish elderly population. Arch Clin Neuropsychol. 2011; 26(3): p. 270–279. https://doi.org/10.1093/acrin/acr011 PMID: 21378378
39. Efron B. Large-Scale Inference: Empirical Bayes Methods for Estimation, Testing and prediction: Stanford University; 2010.
40. Luck SJ. An Introduction to the Event-Related Potential Technique. Cambridge: MIT Press; 2005.
41. Makeig ADS. EEGLAB: an open source toolbox for analysis of. Journal of Neuroscience Methods 134:9–21. 2004. https://doi.org/10.1016/j.jneumeth.2003.10.009 PMID: 15102499
42. Nancy KSquires KCSA. Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. Electroencephalography and Clinical Neurophysiology. April 1975;: p. 387–401.
43. Invitto Sara CAP GC VB MT MM D. Obstructive sleep apnea syndrome and olfactory perception: An OERP study. Respiratory Physiology & Neurobiology. January 2019;: p. 37–44. https://doi.org/10.1016/j.resp.2018.07.002 PMID: 3006255
44. Hojjati H, Sedghizadeh MJ, Ezzatdoost K, Aghajan H. An Inexpensive and Portable Olfactometer for Event-Related Potential Experiments. In Austria International Biomedical Engineering Conference (AiBEC); 2019; Vienna.
45. Cecilia Tremblay JF. Olfactory and Trigeminal Systems Interact in the Periphery. Chemical Senses. October 2018; 43(8): p. 611–616. https://doi.org/10.1093/chemse/bjy049 PMID: 3052799
46. T. S. Lorig ACSJCaWSC. Event-related. Bulletin of Psychonomic Society. 131–134(31(2)): p. 131–134.
47. Caminiti Fabrizia DS SDC MCR MB PM SC R. Detection of Olfactory Dysfunction Using Olfactory Event Related Potentials in Young Patients with Multiple Sclerosis. Plos One. July 21, 2014. https://doi.org/10.1371/journal.pone.0103151 PMID: 25047369
48. Aapo Hyvärinen EO. Independent component analysis: algorithms and applications. Neural Networks 2000.
49. Welch P. The use of fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Transactions on Audio and Electroacoustics, vol. 15, no. 2, pp. 70–73, June 1967.
50. Gupta Y, Lama RK, Kwon GR. Prediction and Classification of Alzheimer’s Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers. Frontiers in Computational Neuroscience. October 16, 2019.
51. Samper-González J, Burgos N, Bottani S, Fontanella S, Lu P, et al. Reproducible evaluation of classification methods in Alzheimer’s disease: Framework and application to MRI and PET data. NeuroImage. 2018; 183: p. 504–521. https://doi.org/10.1016/j.neuroimage.2018.04.042 PMID: 30130647
52. Wolk D, Salloway S, Dickenson B. Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic system to the test. JAMA. 2019; 321(23): p. 2289–2291. https://doi.org/10.1001/jama.2019.7534 PMID: 31211328
53. Fries P, Nikolic D, Singer W. The Gamma Cycle. Trends in Neuroscience. 2007; 30(7): p. 309–316. https://doi.org/10.1016/j.tins.2007.05.005 PMID: 17555828
54. Yuval-Greenberg S, Deouelle LY. What you see is not (always) what you hear: induced gamma band responses reflect cross modal interactions in familiar object recognition. J. Neurosci. 2007; 27: p. 1090–1096. https://doi.org/10.1523/JNEUROSCI.4828-06.2007 PMID: 17267563
55. Mishra J, Martinez A, Sejnowski TJ, Hillyard SA. Early Cross-Modal Interactions in Auditory and Visual Cortex Underlie a Sound-Induced Visual Illusion. Journal of Neuroscience. 2007; 27(15): p. 4120–4131. https://doi.org/10.1523/JNEUROSCI.4912-06.2007 PMID: 17428990
56. Taylor K, Mandon S, Freiwald WA, Kreiter AK. Coherent Oscillatory Activity in Monkey Area V4 Predicts Successful Allocation of Attention. Cerebral Cortex. 2005; 15(9): p. 1424–1437. https://doi.org/10.1093/ercor/bhi023 PMID: 15659657
57. Börgers C, Epstein S, Kopeli NJ. Background gamma rhythmicity and attention in cortical local circuits: A computational study. PNAS. 2005; 102(19): p. 7002–7007. https://doi.org/10.1073/pnas.0502366102 PMID: 15870189
58. Mishra J, Fellous JM, Sejnowski TJ. Selective attention through phase relationship of excitatory and inhibitory input synchrony in a model cortical neuron. Neural Netw. 2006; 19(9): p. 1329–46. https://doi.org/10.1016/j.neunet.2006.08.005 PMID: 17027225
59. Pesaran B, Pezaris JS, Sahani M, Mitra PP, Andersen RA. Temporal structure in neuronal activity during working memory in macaque parietal cortex. Nat Neurosci. 2002; 5(8): p. 805–11. https://doi.org/10.1038/nn890 PMID: 12134152
60. Fell J, Klaver P, Lehnartz K, Grunwald T, Schaller C, Elger CE, et al. Human memory formation is accompanied by thalamic-hippocampal coupling and decoupling. Nat Neurosci. 2001; 4(12): p. 1259–64. https://doi.org/10.1038/nn759 PMID: 11694886
61. Wespatat V, Tennigkeit F, Singer W. Phase sensitivity of synaptic modifications in oscillating cells of rat visual cortex. J. Neurosci. 2004; 24(41): p. 9067–75. https://doi.org/10.1523/JNEUROSCI.2221-04.2004 PMID: 15483125

62. Buzsaki G. Rhythms of the brain: Oxford University Press; 2006.

63. Fries P. A mechanism for cognitive dynamics: neuronal communication through neuronal coherence. Trends in Cognitive Science. 2005; 9: p. 474–480. https://doi.org/10.1016/j.tics.2005.08.011 PMID: 16150631

64. Koenig T, Prichop L, Dierks T, Hafid D, Wahlund LO, John ER, et al. Decreased EEG synchronization in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2005; 26(2): p. 165–171. https://doi.org/10.1016/j.neurobiolaging.2004.03.008 PMID: 15582746

65. Verret L, Mann E, Hang G, Barth A, Cobos I, Ho K, et al. Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model. Cell. 2012; 149(3). https://doi.org/10.1016/j.cell.2012.02.046 PMID: 22541439

66. Uhlhaas PH, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron. 2006; 52(1): p. 155–168. https://doi.org/10.1016/j.neuron.2006.09.020 PMID: 17015233

67. Pijnenburg YA, Made Yv d, van Cappellen van Walsum AM, Knol DL, Scheltens P, Starm CJ. EEG synchronization likelihood in mild cognitive impairment and Alzheimer’s disease during a working memory task. Clin. Neurophysiol. 2004; 115(6): p. 1332–1339. https://doi.org/10.1016/j.clinph.2003.12.029 PMID: 15134700

68. Palop JJ, Chin J, Roberson ED. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007; 55(5): p. 697–711. https://doi.org/10.1016/j.neuron.2007.07.025 PMID: 17785178

69. Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016; p. 230–235. https://doi.org/10.1038/nature20587 PMID: 27929004

70. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012; 149(3): p. 708–721. https://doi.org/10.1016/j.cell.2012.02.046 PMID: 22541439

71. Gillespie AK, Jones EA, Lin YH, Karlsson MP, Kay K, Yoon SY, et al. Apolipoprotein E4 Causes Age-Dependent Disruption of Slow Gamma Oscillations during Hippocampal Sharp-Wave Ripples. Neuron. 2016; 90(4): p. 740–751. https://doi.org/10.1016/j.neuron.2016.04.009 PMID: 27161522

72. Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer’s disease. Nature. 2016; 539: p. 187–196. https://doi.org/10.1038/nature20412 PMID: 27830780

73. Palop JJ, Mucke L. Amyloid-β Induced Neuronal Dysfunction in Alzheimer’s Disease: From Synapses toward Neural Networks. Nature Neuroscience. 2011; 13(7).

74. Musaeus CS, Engedal k, Hogh P, Jelic V, Morup M, Naik M, et al. Oscillatory connectivity as a diagnostic marker of dementia due to Alzheimer’s disease. Clinical Neurophysiology. 2019; 130(10): p. 1889–1899. https://doi.org/10.1016/j.clinph.2019.07.016 PMID: 31408790